IOncology

At SABCS 2024, Dr. Janice Tsang explored key developments in early breast cancer (EBC) treatment, highlighting the transition from conventional approaches to more personalized, biomarker-driven strategies. The discussion addressed de-escalation of radiotherapy, long-term updates on adjuvant therapies, and the expanding role of immunotherapy (IO) in triple-negative breast cancer (TNBC) and high-risk HR+/HER2- disease.

At SABCS 2024, Nan Chen, MD, presented insights from a post-hoc analysis of TAILORx, exploring the role of anthracyclines in high genomic risk, node-negative HR+/HER2- breast cancer. The discussion focused on how Recurrence Score (RS) > 31 may influence treatment decisions and the potential impact of tumor size on chemotherapy benefits. These insights challenge prior assumptions about anthracycline use in HR+ breast cancer and highlight the need for a more personalized approach in high-risk patients.

At SABCS 2024, Dr. Judy Garber presented the latest 10-year follow-up results from the OlympiA trial, which continue to reinforce the role of adjuvant olaparib in patients with germline BRCA1/2 mutation-associated, high-risk HER2-negative breast cancer. With a median follow-up of 6.1 years (maximum 9.6 years), the trial confirms the long-term benefits of olaparib in reducing recurrence and improving survival outcomes.

The final results of the KEYNOTE-522 trial confirm the potential of pembrolizumab to change patient management, though careful patient selection and toxicity monitoring are essential.

Editor’s Note: Primary hepatocellular carcinoma (HCC) is a prevalent malignant tumor, and combining systemic therapy, immunotherapy, and regional local treatment is guiding HCC clinical treatment to new heights. At the recent 18th International Liver Cancer Association (ILCA) Annual Meeting, Dr. Tao Peng from the Hepatobiliary Surgery Department of The First Affiliated Hospital of Guangxi Medical University shared findings from a preliminary clinical trial targeting multinodular HCC. This study explored the use of cadonilimab (Cadonilimab) combined with the FOLFOX regimen via hepatic artery infusion chemotherapy (HAIC) as a neoadjuvant treatment, aimed at providing a more effective treatment strategy for resectable multinodular HCC patients. Oncology Frontier invited Dr. Tao Peng to discuss the main findings and clinical significance of the study.

On November 15, 2024, the 4th International Congress of the Asian Oncology Society (AOS 2024) opened in Xi'an, China, co-hosted by the Chinese Anti-Cancer Association and the Asian Oncology Society. Under the theme "Integration and Modernity," the conference brought together leading oncology experts from across Asia and the globe, fostering academic collaboration and advancing cancer research.

New data from the NATALEE trial reinforce the efficacy of ribociclib in combination with endocrine therapy for HR-positive, HER2-negative early breast cancer. With a median follow-up of 33.3 months, the…

New findings from the KATHERINE trial, published in The New England Journal of Medicine, confirm that trastuzumab emtansine (T-DM1) continues to provide superior survival benefits over trastuzumab alone in HER2-positive…

At the recently held 2024 Precision Medicine Conference on Lung Cancer, Dr. Nan Bi from the Cancer Hospital Chinese Academy of Medical Sciences, delivered a presentation titled "Advances in Radiotherapy for NSCLC in 2024." The talk covered key developments in radiotherapy combined with targeted therapy, radiotherapy combined with immunotherapy, and technological advancements in radiotherapy. In an exclusive interview with Oncology Frontier, Professor Bi further elaborated on some of the most pressing topics in this evolving field.

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. For patients with unresectable HCC, transarterial chemoembolization (TACE) is a standard treatment. The phase 2, multicenter, open-label, randomized CARES-005…